Naobios
Overview and capabilities of Naobios
Naobios provides bioprocess development and contract manufacturing services for viral vaccines and viral vectors. The company was acquired by Clean Biologics on March 1st, 2019 and now supports clients for process development and the manufacture of preclinical and clinical batches.
In the news
See all news
Clean Mails – December 2022
Naobios signs a Research License Agreement with Valneva on EB66® cell line.
Naobios today announces the signature of a Research License Agreement with Valneva to assess the EB66® cell line as cell substrate for the evaluation of alternative bioprocess design and new technologies.
Clean Mails – December 2022
Naobios, your partner in the production of Human Viral Challenge Agents
Naobios today announces its investment in the manufacturing of Human Viral Challenge Agents.
Clean Biologics was born in 2018 from a fruitful alliance between Clean Cells and Archimed. Through this partnership, the group soon acquired and integrated CDMO Naobios to extend the service offer and to promote our future-oriented thinking. The expertise, transparency, progress and a human-centred view are at the core of our identity. Day after day, we use our knowledge and our skills to deliver high-quality services in innovative projects with an unwavering dynamism and commitment.
Over 15 Years
History in GMP and Process Development Activities
A team
of 40 people